You are here

Article Text

Article menu
Download PDFPDF
Letter
Empiric NSU treatment needs updating
  1. Sally Murray,
  2. Lewis Marshall
  1. Infectious Disease Department, B2 Clinic, Fremantle Hospital, Perth, Western Australia, Australia
  1. Correspondence to Dr Lewis Marshall, Infectious Disease Department, B2 Clinic, Fremantle Hospital, Alma St, Fremantle, Perth, WA 6159, Australia; Lewis.Marshall{at}health.wa.gov.au

https://doi.org/10.1136/sextrans-2014-051560

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The recent paper by Khosropour et al 1 highlighted current management issues related to non-specific urethritis (NSU) treatment and adherence. It follows accumulating recent literature surrounding the management of NSU, especially with regard to Mycoplasma genitalium urethritis, where studies highlight significant treatment failure using standard doxycyline (100 mg bd for 10 days) and azithromycin 1 g …

    View Full Text

    Footnotes

    • Contributors Both authors contributed equally to the manuscript.

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.